ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

David E. Gerber, MD, and James L. Mulshine, MD, on Bringing Genomic Discovery and Targeted Therapies to Early-Stage Lung Cancer

James L. Mulshine, MD, of Rush University Medical Center, and David E. Gerber, MD, of The University of Texas Southwestern Medical Center, discuss the ALCHEMIST trial, an NCI initiative to address the role of molecular testing and targeted therapies for earlier-stage lung disease (Abstract TPS7583).

Survivorship

Gregory T. Armstrong, MD, MSCE, and Lisa Diller, MD

Gregory T. Armstrong, MD, MSCE, and Lisa Diller, MD, on Reduction of Late Mortality in Childhood Cancer Survivors

Lisa Diller, MD, of Dana-Farber Cancer Institute, and Gregory T. Armstrong, MD, MSCE, of St. Jude Children's Research Hospital, discuss the findings of a landmark survivorship study (Abstract LBA2).

Hematologic Malignancies

Palliative Care

Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM

Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM, on Palliative Care for Patients With Hematologic Malignancies

Thomas W. LeBlanc, MD, of Duke University Medical Center, and Eric Roeland, MD, FAAHPM, of the University of California, San Diego Moores Cancer Center, discuss the use of palliative and hospice care for patients with solid tumors vs hematologic cancers and clinicians’ attitudes (Abstracts e20554 and 9524).

Breast Cancer

Nicholas C. Turner, MD, PhD

Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital NHS Trust, discusses fulvestrant and palbociclib as a treatment option in pre- and postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (Abstract LBA502).

Lymphoma

Laurie H. Sehn, MD, MPH

Laurie Helen Sehn, MD, MPH, Summarizes Results of the GADOLIN Trial on Indolent NHL

Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a first-ever finding on obinutuzumab and bendamustine in the setting of rituximab-refractory indolent non-Hodgkin lymphoma (Abstract LBA8502).

Aug

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

David E. Gerber, MD, and James L. Mulshine, MD, on Bringing Genomic Discovery and Targeted Therapies to Early-Stage Lung Cancer

Gregory T. Armstrong, MD, MSCE, and Lisa Diller, MD, on Reduction of Late Mortality in Childhood Cancer Survivors

Thomas W. LeBlanc, MD, and Eric Roeland, MD, FAAHPM, on Palliative Care for Patients With Hematologic Malignancies

Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study

Laurie Helen Sehn, MD, MPH, Summarizes Results of the GADOLIN Trial on Indolent NHL

Darovasertib Plus Crizotinib May Set New First-Line Standard in HLA-A2–Negative Metastatic Uveal Melanoma

AASLD Publishes Landmark North American Framework to Advance Treatment Decisions for HCC

AI Model Predicts TP53 Status Tumor Type and Survival From Routine HE Slides

Adding Irinotecan to Preoperative Chemoradiotherapy Does Not Improve Outcomes in Locally Advanced Rectal Cancer

Early Intravesical Pirarubicin Improves Relapse-Free Survival in Upper Tract Urothelial Carcinoma